艾迪藥業(688488.SH)擬推第一期員工持股計劃
格隆匯2月8日丨艾迪藥業(688488.SH)發佈第一期員工持股計劃(草案),本員工持股計劃的資金來源為公司提取的激勵基金。公司將提取金額為不超過人民幣200萬元的激勵基金,劃入員工持股計劃資金賬户,以員工持股計劃證券賬户購買公司股票。鎖定期12個月,存續期不超過24個月。
員工持股計劃的參與對象包括公司(含控股子公司,下同)董事(不含獨立董事)、監事、高級管理人員、核心技術(業務)骨幹人員及董事會認定的其他人員。參加本次持股計劃的總人數不超過21人,其中董事(不含獨立董事)1人,其他員工不超過20人,最終參加員工持股計劃的員工人數以實際執行情況為準。
本員工持股計劃以“份”作為認購單位,每份份額為1元,員工持股計劃的總份數為不超過200萬份。本員工持股計劃的參與對象將以0元/份的對價認購每份份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.